Histological transformation to signet-ring cell carcinoma in a patient with clinically aggressive poorly differentiated adenocarcinoma of the ascending colon after response to chemotherapy plus cetuximab: a case report.
Ascending colon cancer
Cetuximab
Chemotherapy
Histological transformation
Poorly differentiated adenocarcinoma
Signet-ring cell carcinoma
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
07 Jun 2023
07 Jun 2023
Historique:
received:
07
03
2023
accepted:
26
05
2023
medline:
8
6
2023
pubmed:
7
6
2023
entrez:
6
6
2023
Statut:
epublish
Résumé
Alteration of chemosensitivity or tumor aggressiveness in response to chemotherapy has been reported, and liquid biopsy assessment during chemotherapy for colorectal cancers has confirmed the acquisition of mutations in various oncogenes. However, the occurrence of histological transformation seems to be extremely rare in colorectal cancers, and the few existing case reports of this transformation are from lung cancer and breast cancer. In this report, we describe the histological transformation of clinically aggressive scirrhous-type poorly differentiated adenocarcinoma of the ascending colon to signet-ring cell carcinoma in almost all recurrent tumors that were confirmed by autopsy after response to chemotherapy plus cetuximab. A 59-year-old woman visited our hospital with whole abdominal pain and body weight loss and was diagnosed with scirrhous-type poorly differentiated adenocarcinoma of the ascending colon with aggressive lymph node metastases. The intrinsic chemosensitivity of the tumors was evident upon initiation of mFOLFOX6 plus cetuximab therapy, and right hemicolectomy was performed, and the tumor obviously remained in the peripancreatic area, paraaortic region, or other retroperitoneal areas. The ascending colon tumors mainly consisted of poorly differentiated adenocarcinoma and were not associated with signet-ring cell components except for minute clusters in a few lymphatic emboli in the main tumor. Chemotherapy was continued, and metastases were eliminated at 8 months after the operation; this response was maintained for an additional 4 months. Discontinuation of chemotherapy plus cetuximab resulted in immediate tumor recurrence and rapid expansion, and the patient died of the recurrent tumor 1 year and 2 months after the operation. Autopsy specimens revealed that almost all of the recurrent tumors exhibited transformation and consisted of signet-ring cell histology. This case might suggest that various oncogene mutations or epigenetic changes resulting from chemotherapy, especially regimens that include cetuximab, contribute to the transformation of non-signet-ring cell colorectal carcinoma to signet-ring cell carcinoma histology and can promote the aggressive clinical progression characteristic of signet-ring cell carcinoma.
Sections du résumé
BACKGROUND
BACKGROUND
Alteration of chemosensitivity or tumor aggressiveness in response to chemotherapy has been reported, and liquid biopsy assessment during chemotherapy for colorectal cancers has confirmed the acquisition of mutations in various oncogenes. However, the occurrence of histological transformation seems to be extremely rare in colorectal cancers, and the few existing case reports of this transformation are from lung cancer and breast cancer. In this report, we describe the histological transformation of clinically aggressive scirrhous-type poorly differentiated adenocarcinoma of the ascending colon to signet-ring cell carcinoma in almost all recurrent tumors that were confirmed by autopsy after response to chemotherapy plus cetuximab.
CASE PRESENTATION
METHODS
A 59-year-old woman visited our hospital with whole abdominal pain and body weight loss and was diagnosed with scirrhous-type poorly differentiated adenocarcinoma of the ascending colon with aggressive lymph node metastases. The intrinsic chemosensitivity of the tumors was evident upon initiation of mFOLFOX6 plus cetuximab therapy, and right hemicolectomy was performed, and the tumor obviously remained in the peripancreatic area, paraaortic region, or other retroperitoneal areas. The ascending colon tumors mainly consisted of poorly differentiated adenocarcinoma and were not associated with signet-ring cell components except for minute clusters in a few lymphatic emboli in the main tumor. Chemotherapy was continued, and metastases were eliminated at 8 months after the operation; this response was maintained for an additional 4 months. Discontinuation of chemotherapy plus cetuximab resulted in immediate tumor recurrence and rapid expansion, and the patient died of the recurrent tumor 1 year and 2 months after the operation. Autopsy specimens revealed that almost all of the recurrent tumors exhibited transformation and consisted of signet-ring cell histology.
CONCLUSION
CONCLUSIONS
This case might suggest that various oncogene mutations or epigenetic changes resulting from chemotherapy, especially regimens that include cetuximab, contribute to the transformation of non-signet-ring cell colorectal carcinoma to signet-ring cell carcinoma histology and can promote the aggressive clinical progression characteristic of signet-ring cell carcinoma.
Identifiants
pubmed: 37280577
doi: 10.1186/s12957-023-03053-2
pii: 10.1186/s12957-023-03053-2
pmc: PMC10245628
doi:
Substances chimiques
Cetuximab
PQX0D8J21J
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
172Informations de copyright
© 2023. The Author(s).
Références
J Gastrointest Oncol. 2014 Feb;5(1):18-24
pubmed: 24490039
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Acta Pathol Jpn. 1987 Oct;37(10):1679-84
pubmed: 2829503
Breast Cancer Res Treat. 2003 Aug;80(3):267-73
pubmed: 14503799
Sci Rep. 2019 Oct 25;9(1):15365
pubmed: 31653970
J Clin Oncol. 2005 Dec 1;23(34):8688-96
pubmed: 16246976
J Cancer. 2017 Feb 10;8(3):388-394
pubmed: 28261339
Nat Rev Clin Oncol. 2017 Sep;14(9):531-548
pubmed: 28252003
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Ann Oncol. 2017 Jun 01;28(6):1325-1332
pubmed: 28419195
Cancer Cell. 2017 Feb 13;31(2):172-179
pubmed: 28196593
Ann Thorac Surg. 2015 Jan;99(1):316-9
pubmed: 25555954
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Cancer. 2019 Dec 1;125(23):4139-4147
pubmed: 31433498
Dis Colon Rectum. 1983 Aug;26(8):529-32
pubmed: 6307611
Nat Rev Cancer. 2008 Oct;8(10):755-68
pubmed: 18784658
J Thorac Oncol. 2015 Sep;10(9):e86-e88
pubmed: 26291017
Intest Res. 2015 Oct;13(4):332-8
pubmed: 26576139
Langenbecks Arch Surg. 2004 Jun;389(3):178-83
pubmed: 15188084
J Pathol. 2007 Jul;212(3):278-86
pubmed: 17471475
Nature. 2012 Jun 28;486(7404):532-6
pubmed: 22722830
Pathol Oncol Res. 2021 Jul 26;27:1609859
pubmed: 34381313
Sci Transl Med. 2011 Mar 23;3(75):75ra26
pubmed: 21430269